Humacyte, Inc. (HUMA) 10-Year Financial Performance & Capital Metrics

HUMA • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Show more

Revenue $0
EBITDA -$107M -16.1%
Net Income -$149M -34.2%
EPS (Diluted) -1.26 -17.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -12.33 +18.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Shares diluted 14.6% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM75.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM82.84%

ROCE

10Y Avg-59.04%

5Y Avg-59.99%

3Y Avg-68.39%

Latest-100.48%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6.19M	1.49M	1.26M	1.56M	0	0
Revenue Growth %	-	-0.76%	-0.15%	0.24%	-1%	-
Cost of Goods Sold+	75.6M	54.08M	61.34M	8.26M	76.55M	7.19M
COGS % of Revenue	12.22%	36.27%	48.57%	5.27%	-	-
Gross Profit+	-69.42M	-52.59M	-60.08M	-6.69M	-76.55M	-7.19M
Gross Margin %	-11.22%	-35.27%	-47.57%	-4.27%	-	-
Gross Profit Growth %	-	0.24%	-0.14%	0.89%	-10.44%	0.91%
Operating Expenses+	16.27M	12.01M	21.13M	77.89M	23.5M	107.21M
OpEx % of Revenue	2.63%	8.06%	16.73%	49.77%	-	-
Selling, General & Admin	16.27M	12.01M	21.13M	22.88M	20.39M	25.8M
SG&A % of Revenue	2.63%	8.06%	16.73%	14.62%	-	-
Research & Development	75.6M	54.08M	61.34M	63.26M	76.55M	88.6M
R&D % of Revenue	12.22%	36.27%	48.57%	40.42%	-	-
Other Operating Expenses	-75.6M	-54.08M	-61.34M	-8.26M	-73.44M	-7.19M
Operating Income+	-85.69M	-64.6M	-81.21M	-84.58M	-100.05M	-114.4M
Operating Margin %	-13.85%	-43.33%	-64.3%	-54.04%	-	-
Operating Income Growth %	-	0.25%	-0.26%	-0.04%	-0.18%	-0.14%
EBITDA+	-78.94M	-56.25M	-72.97M	-76.37M	-92.33M	-107.21M
EBITDA Margin %	-12.76%	-37.73%	-57.77%	-48.8%	-	-
EBITDA Growth %	-	0.29%	-0.3%	-0.05%	-0.21%	-0.16%
D&A (Non-Cash Add-back)	6.75M	8.35M	8.24M	8.21M	7.72M	7.19M
EBIT	-85.69M	-64.6M	-81.21M	-84.58M	-104.18M	-139.42M
Net Interest Income+	-2.03M	-1.92M	-4.33M	-3.57M	-1.13M	-5.17M
Interest Income	269K	278K	16K	2.63M	5.47M	4.1M
Interest Expense	2.3M	2.2M	4.35M	6.2M	6.6M	9.28M
Other Income/Expense	269K	-1.92M	54.73M	72.61M	-10.73M	-34.3M
Pretax Income+	-85.42M	-66.52M	-26.48M	-11.96M	-110.78M	-148.7M
Pretax Margin %	-13.81%	-44.62%	-20.96%	-7.65%	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-85.42M	-66.52M	-26.48M	-11.96M	-110.78M	-148.7M
Net Margin %	-13.81%	-44.62%	-20.96%	-7.65%	-	-
Net Income Growth %	-	0.22%	0.6%	0.55%	-8.26%	-0.34%
Net Income (Continuing)	-85.42M	-66.52M	-26.48M	-11.96M	-110.78M	-148.7M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-4.25	-5.52	-0.66	-0.12	-1.07	-1.26
EPS Growth %	-	-0.3%	0.88%	0.82%	-7.92%	-0.18%
EPS (Basic)	-4.25	-5.52	-0.66	-0.12	-1.07	-1.26
Diluted Shares Outstanding	20.12M	12.45M	39.97M	103.05M	103.42M	118.48M
Basic Shares Outstanding	20.12M	12.45M	39.97M	103.05M	103.42M	118.48M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	94.95M	41.45M	229.34M	154.21M	83.28M	47.86M
Cash & Short-Term Investments	93.71M	39.93M	225.5M	151.88M	80.45M	44.94M
Cash Only	93.71M	39.93M	217.5M	149.77M	80.45M	44.94M
Short-Term Investments	0	0	8M	2.11M	0	0
Accounts Receivable	601K	113K	176K	31K	0	0
Days Sales Outstanding	35.46	27.66	50.86	7.23	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	2.3M	2.83M	2.92M
Total Non-Current Assets+	73.74M	65.24M	57.19M	50.09M	44.95M	90.01M
Property, Plant & Equipment	73.74M	65.24M	57.19M	50.09M	44.1M	38.55M
Fixed Asset Turnover	0.08x	0.02x	0.02x	0.03x	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	841K	51.46M
Total Assets+	168.69M	106.69M	286.53M	204.3M	128.22M	137.87M
Asset Turnover	0.04x	0.01x	0.00x	0.01x	-	-
Asset Growth %	-	-0.37%	1.69%	-0.29%	-0.37%	0.08%
Total Current Liabilities+	10.84M	11.23M	11.05M	19.58M	18.44M	19.95M
Accounts Payable	3.27M	2.27M	2.09M	1.59M	6.49M	4.49M
Days Payables Outstanding	15.8	15.35	12.46	70.52	30.95	227.93
Short-Term Debt	1.5M	2.45M	0	8.57M	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	-1.5M	1.15M	4.12M	4.23M	5.29M	7.37M
Current Ratio	8.76x	3.69x	20.75x	7.88x	4.52x	2.40x
Quick Ratio	8.76x	3.69x	20.75x	7.88x	4.52x	2.40x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	25.65M	24.78M	153.31M	67.79M	96.23M	170.59M
Long-Term Debt	0	822K	27.36M	20.34M	38.6M	0
Capital Lease Obligations	25.65M	23.82M	21.79M	18.85M	16.29M	13.62M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	144K	104.16M	28.61M	41.34M	156.97M
Total Liabilities	36.49M	36.02M	164.36M	87.37M	114.68M	190.54M
Total Debt+	28.72M	28.86M	51.18M	50.07M	57.45M	16.54M
Net Debt	-65M	-11.07M	-166.32M	-99.71M	-23M	-28.4M
Debt / Equity	0.22x	0.41x	0.42x	0.43x	4.24x	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-37.29x	-29.34x	-18.68x	-13.64x	-15.16x	-12.33x
Total Equity+	132.2M	70.67M	122.17M	116.93M	13.55M	-52.67M
Equity Growth %	-	-0.47%	0.73%	-0.04%	-0.88%	-4.89%
Book Value per Share	6.57	5.68	3.06	1.13	0.13	-0.44
Total Shareholders' Equity	132.2M	70.67M	122.17M	116.93M	13.55M	-52.67M
Common Stock	21K	1K	10K	10K	10K	13K
Retained Earnings	-321.57M	-388.1M	-414.57M	-426.54M	-537.31M	-686.01M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-71.79M	-55.57M	-81.19M	-71.13M	-73.31M	-98.12M
Operating CF Margin %	-11.6%	-37.27%	-64.28%	-45.45%	-	-
Operating CF Growth %	-	0.23%	-0.46%	0.12%	-0.03%	-0.34%
Net Income	-85.42M	-66.52M	-26.48M	-11.96M	-110.78M	-148.7M
Depreciation & Amortization	6.75M	8.43M	8.24M	8.21M	7.72M	7.19M
Stock-Based Compensation	4.46M	0	10.15M	6.18M	0	6.14M
Deferred Taxes	-4.27M	0	0	0	0	0
Other Non-Cash Items	6.25M	4.89M	-72.54M	-74.59M	23.18M	36.94M
Working Capital Changes	453K	-2.37M	-557K	1.03M	6.57M	311K
Change in Receivables	-185K	488K	-63K	145K	31K	0
Change in Inventory	-2.43M	0	0	0	0	0
Change in Payables	2.43M	-889K	-197K	-509K	4.81M	-1.96M
Cash from Investing+	-8.13M	-268K	-8.22M	4.84M	-173K	-1.57M
Capital Expenditures	-8.13M	-318K	-220K	-1.05M	-2.28M	-1.57M
CapEx % of Revenue	1.31%	0.21%	0.17%	0.67%	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	-74K	2.05M	266.98M	-1.45M	4.51M	114.18M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	1.22M	0	239.05M	535K	-1.76M	27.71M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-79.91M	-55.89M	-81.41M	-72.18M	-75.58M	-99.69M
FCF Margin %	-12.92%	-37.48%	-64.46%	-46.12%	-	-
FCF Growth %	-	0.3%	-0.46%	0.11%	-0.05%	-0.32%
FCF per Share	-3.97	-4.49	-2.04	-0.70	-0.73	-0.84
FCF Conversion (FCF/Net Income)	0.84x	0.84x	3.07x	5.94x	0.66x	0.66x
Interest Paid	0	0	1.12M	2.67M	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-64.62%	-65.58%	-27.46%	-10.01%	-169.81%	-
Return on Invested Capital (ROIC)	-	-76.41%	-788.22%	-	-1930.66%	-
Gross Margin	-1121.97%	-3526.96%	-4756.77%	-427.48%	-	-
Net Margin	-1380.67%	-4461.7%	-2096.36%	-764.54%	-	-
Debt / Equity	0.22x	0.41x	0.42x	0.43x	4.24x	-
Interest Coverage	-37.29x	-29.34x	-18.68x	-13.64x	-15.16x	-12.33x
FCF Conversion	0.84x	0.84x	3.07x	5.94x	0.66x	0.66x
Revenue Growth	-	-75.9%	-15.29%	23.91%	-100%	-

Frequently Asked Questions

Growth & Financials

Humacyte, Inc. (HUMA) reported $8.8M in revenue for fiscal year 2024. This represents a 42% increase from $6.2M in 2019.

Humacyte, Inc. (HUMA) grew revenue by 0.0% over the past year. Growth has been modest.

Humacyte, Inc. (HUMA) reported a net loss of $37.0M for fiscal year 2024.

Dividend & Returns

Humacyte, Inc. (HUMA) had negative free cash flow of $106.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Humacyte, Inc. (HUMA) 10-Year Financial Performance & Capital Metrics

HUMA • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $0
EBITDA -$107M -16.1%
Net Income -$149M -34.2%
EPS (Diluted) -1.26 -17.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -12.33 +18.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Shares diluted 14.6% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM75.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM82.84%

ROCE

10Y Avg-59.04%

5Y Avg-59.99%

3Y Avg-68.39%

Latest-100.48%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6.19M	1.49M	1.26M	1.56M	0	0
Revenue Growth %	-	-0.76%	-0.15%	0.24%	-1%	-
Cost of Goods Sold+	75.6M	54.08M	61.34M	8.26M	76.55M	7.19M
COGS % of Revenue	12.22%	36.27%	48.57%	5.27%	-	-
Gross Profit+	-69.42M	-52.59M	-60.08M	-6.69M	-76.55M	-7.19M
Gross Margin %	-11.22%	-35.27%	-47.57%	-4.27%	-	-
Gross Profit Growth %	-	0.24%	-0.14%	0.89%	-10.44%	0.91%
Operating Expenses+	16.27M	12.01M	21.13M	77.89M	23.5M	107.21M
OpEx % of Revenue	2.63%	8.06%	16.73%	49.77%	-	-
Selling, General & Admin	16.27M	12.01M	21.13M	22.88M	20.39M	25.8M
SG&A % of Revenue	2.63%	8.06%	16.73%	14.62%	-	-
Research & Development	75.6M	54.08M	61.34M	63.26M	76.55M	88.6M
R&D % of Revenue	12.22%	36.27%	48.57%	40.42%	-	-
Other Operating Expenses	-75.6M	-54.08M	-61.34M	-8.26M	-73.44M	-7.19M
Operating Income+	-85.69M	-64.6M	-81.21M	-84.58M	-100.05M	-114.4M
Operating Margin %	-13.85%	-43.33%	-64.3%	-54.04%	-	-
Operating Income Growth %	-	0.25%	-0.26%	-0.04%	-0.18%	-0.14%
EBITDA+	-78.94M	-56.25M	-72.97M	-76.37M	-92.33M	-107.21M
EBITDA Margin %	-12.76%	-37.73%	-57.77%	-48.8%	-	-
EBITDA Growth %	-	0.29%	-0.3%	-0.05%	-0.21%	-0.16%
D&A (Non-Cash Add-back)	6.75M	8.35M	8.24M	8.21M	7.72M	7.19M
EBIT	-85.69M	-64.6M	-81.21M	-84.58M	-104.18M	-139.42M
Net Interest Income+	-2.03M	-1.92M	-4.33M	-3.57M	-1.13M	-5.17M
Interest Income	269K	278K	16K	2.63M	5.47M	4.1M
Interest Expense	2.3M	2.2M	4.35M	6.2M	6.6M	9.28M
Other Income/Expense	269K	-1.92M	54.73M	72.61M	-10.73M	-34.3M
Pretax Income+	-85.42M	-66.52M	-26.48M	-11.96M	-110.78M	-148.7M
Pretax Margin %	-13.81%	-44.62%	-20.96%	-7.65%	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-85.42M	-66.52M	-26.48M	-11.96M	-110.78M	-148.7M
Net Margin %	-13.81%	-44.62%	-20.96%	-7.65%	-	-
Net Income Growth %	-	0.22%	0.6%	0.55%	-8.26%	-0.34%
Net Income (Continuing)	-85.42M	-66.52M	-26.48M	-11.96M	-110.78M	-148.7M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-4.25	-5.52	-0.66	-0.12	-1.07	-1.26
EPS Growth %	-	-0.3%	0.88%	0.82%	-7.92%	-0.18%
EPS (Basic)	-4.25	-5.52	-0.66	-0.12	-1.07	-1.26
Diluted Shares Outstanding	20.12M	12.45M	39.97M	103.05M	103.42M	118.48M
Basic Shares Outstanding	20.12M	12.45M	39.97M	103.05M	103.42M	118.48M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	94.95M	41.45M	229.34M	154.21M	83.28M	47.86M
Cash & Short-Term Investments	93.71M	39.93M	225.5M	151.88M	80.45M	44.94M
Cash Only	93.71M	39.93M	217.5M	149.77M	80.45M	44.94M
Short-Term Investments	0	0	8M	2.11M	0	0
Accounts Receivable	601K	113K	176K	31K	0	0
Days Sales Outstanding	35.46	27.66	50.86	7.23	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	2.3M	2.83M	2.92M
Total Non-Current Assets+	73.74M	65.24M	57.19M	50.09M	44.95M	90.01M
Property, Plant & Equipment	73.74M	65.24M	57.19M	50.09M	44.1M	38.55M
Fixed Asset Turnover	0.08x	0.02x	0.02x	0.03x	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	841K	51.46M
Total Assets+	168.69M	106.69M	286.53M	204.3M	128.22M	137.87M
Asset Turnover	0.04x	0.01x	0.00x	0.01x	-	-
Asset Growth %	-	-0.37%	1.69%	-0.29%	-0.37%	0.08%
Total Current Liabilities+	10.84M	11.23M	11.05M	19.58M	18.44M	19.95M
Accounts Payable	3.27M	2.27M	2.09M	1.59M	6.49M	4.49M
Days Payables Outstanding	15.8	15.35	12.46	70.52	30.95	227.93
Short-Term Debt	1.5M	2.45M	0	8.57M	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	-1.5M	1.15M	4.12M	4.23M	5.29M	7.37M
Current Ratio	8.76x	3.69x	20.75x	7.88x	4.52x	2.40x
Quick Ratio	8.76x	3.69x	20.75x	7.88x	4.52x	2.40x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	25.65M	24.78M	153.31M	67.79M	96.23M	170.59M
Long-Term Debt	0	822K	27.36M	20.34M	38.6M	0
Capital Lease Obligations	25.65M	23.82M	21.79M	18.85M	16.29M	13.62M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	144K	104.16M	28.61M	41.34M	156.97M
Total Liabilities	36.49M	36.02M	164.36M	87.37M	114.68M	190.54M
Total Debt+	28.72M	28.86M	51.18M	50.07M	57.45M	16.54M
Net Debt	-65M	-11.07M	-166.32M	-99.71M	-23M	-28.4M
Debt / Equity	0.22x	0.41x	0.42x	0.43x	4.24x	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-37.29x	-29.34x	-18.68x	-13.64x	-15.16x	-12.33x
Total Equity+	132.2M	70.67M	122.17M	116.93M	13.55M	-52.67M
Equity Growth %	-	-0.47%	0.73%	-0.04%	-0.88%	-4.89%
Book Value per Share	6.57	5.68	3.06	1.13	0.13	-0.44
Total Shareholders' Equity	132.2M	70.67M	122.17M	116.93M	13.55M	-52.67M
Common Stock	21K	1K	10K	10K	10K	13K
Retained Earnings	-321.57M	-388.1M	-414.57M	-426.54M	-537.31M	-686.01M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-71.79M	-55.57M	-81.19M	-71.13M	-73.31M	-98.12M
Operating CF Margin %	-11.6%	-37.27%	-64.28%	-45.45%	-	-
Operating CF Growth %	-	0.23%	-0.46%	0.12%	-0.03%	-0.34%
Net Income	-85.42M	-66.52M	-26.48M	-11.96M	-110.78M	-148.7M
Depreciation & Amortization	6.75M	8.43M	8.24M	8.21M	7.72M	7.19M
Stock-Based Compensation	4.46M	0	10.15M	6.18M	0	6.14M
Deferred Taxes	-4.27M	0	0	0	0	0
Other Non-Cash Items	6.25M	4.89M	-72.54M	-74.59M	23.18M	36.94M
Working Capital Changes	453K	-2.37M	-557K	1.03M	6.57M	311K
Change in Receivables	-185K	488K	-63K	145K	31K	0
Change in Inventory	-2.43M	0	0	0	0	0
Change in Payables	2.43M	-889K	-197K	-509K	4.81M	-1.96M
Cash from Investing+	-8.13M	-268K	-8.22M	4.84M	-173K	-1.57M
Capital Expenditures	-8.13M	-318K	-220K	-1.05M	-2.28M	-1.57M
CapEx % of Revenue	1.31%	0.21%	0.17%	0.67%	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	-74K	2.05M	266.98M	-1.45M	4.51M	114.18M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	1.22M	0	239.05M	535K	-1.76M	27.71M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-79.91M	-55.89M	-81.41M	-72.18M	-75.58M	-99.69M
FCF Margin %	-12.92%	-37.48%	-64.46%	-46.12%	-	-
FCF Growth %	-	0.3%	-0.46%	0.11%	-0.05%	-0.32%
FCF per Share	-3.97	-4.49	-2.04	-0.70	-0.73	-0.84
FCF Conversion (FCF/Net Income)	0.84x	0.84x	3.07x	5.94x	0.66x	0.66x
Interest Paid	0	0	1.12M	2.67M	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-64.62%	-65.58%	-27.46%	-10.01%	-169.81%	-
Return on Invested Capital (ROIC)	-	-76.41%	-788.22%	-	-1930.66%	-
Gross Margin	-1121.97%	-3526.96%	-4756.77%	-427.48%	-	-
Net Margin	-1380.67%	-4461.7%	-2096.36%	-764.54%	-	-
Debt / Equity	0.22x	0.41x	0.42x	0.43x	4.24x	-
Interest Coverage	-37.29x	-29.34x	-18.68x	-13.64x	-15.16x	-12.33x
FCF Conversion	0.84x	0.84x	3.07x	5.94x	0.66x	0.66x
Revenue Growth	-	-75.9%	-15.29%	23.91%	-100%	-

Frequently Asked Questions

Growth & Financials

Humacyte, Inc. (HUMA) reported $8.8M in revenue for fiscal year 2024. This represents a 42% increase from $6.2M in 2019.

Humacyte, Inc. (HUMA) grew revenue by 0.0% over the past year. Growth has been modest.

Humacyte, Inc. (HUMA) reported a net loss of $37.0M for fiscal year 2024.

Dividend & Returns

Humacyte, Inc. (HUMA) had negative free cash flow of $106.4M in fiscal year 2024, likely due to heavy capital investments.